

(SUPPLEMENTARY TABLE 1) Study Subjects

<u>STUDY POPULATION</u>	<u>CD cases</u>	<u>controls</u>
<u>Primary dataset:</u>		
Samples Received		
Recruited by MAAIS	227	201
Subjects not included		
< 15% African Ancestry	0	1
Final primary dataset		
Study Population	227	200
<u>Secondary dataset:</u>		
Samples Received		
Univ. of Chicago	66	0
Med Coll of Wisconsin	59	0
Duke University	12	0
IBDGC (22 UC and IC cases also received)	14	7
Balt. Asthma Controls	0	152
Total Samples cohort 2 received	151	159
Subjects not included		
≤ 15% African Ancestry	2	1
Canadian IBDGC study subjects	12	4
Poor genotyping	10	0
Final secondary dataset		
Study Population	127	154

(SUPPLEMENTARY TABLE 2) Characteristics of 21 SNPs genotyped (combined dataset)

Gene	SNP no.	Nucleotide change	Location	Minor allele frequency (in controls)	Genotype call rate	HWE <i>P</i>	HapMap CEU	HapMap YRI
Candidate SNPs								
<i>NOD2</i>	Rs2066847 1007fs (SNP13)	3020insC [-/C]	Exon11	Allele “+”: 0.1%	99.2%	0.98	-: 100% +: 0%	-: 100% +: 0%
<i>NOD2</i>	Rs2066845 G908R (SNP12)	C/G	Exon8	Allele “C”: 0.3%	98.9%	0.96	C: 1.7% G: 98.3%	C: 0% G: 100%
<i>NOD2</i>	Rs2066844 R702W (SNP8)	C/T	Exon4	Allele “T”: 0.6%	95.5%	0.92	C: 89% T: 11%	C: 100% T: 0%
<i>NOD2</i>	Rs2066842 P268S (SNP5)	C/T (ancestral allele C)	Exon4	Allele “T”: 4.4%	98.9%	0.38	C: 63.8% T: 36.2%	C: 100% T: 0%
<i>NOD2</i>	rs35285618 R708H	A/G	Exon4	Allele “A”: 1.4%	95.5%	0.80	--	--
<i>NOD2</i>	rs5743279 R790Q	A/G (ancestral allele G)	Exon4	Allele “A”: 4.0%	95%	0.04	A: 0% G: 100%	A: 2.5% G: 97.5%
<i>NOD2</i>	rs5743278 A725G	C/G (ancestral allele C)	Exon4	Allele “G”: 4.4%	95.5%	0.63	C: 100% G: 0%	C: 91.7% G: 8.3%
<i>ATG16L1</i>	Rs2241880 Thr300Ala	A/G (ancestral allele T)	Exon8	Allele “G”:29.3%	98.6%	0.72	T: 45.8% C: 54.2%	T: 72.5% C: 27.5%
<i>IBD5_OCTN1</i> <i>SLC22A4</i>	Rs1050152 Leu503Phe	C/T (ancestral allele C)	Exon9	Allele “T”: 7.6%	98.9%	0.44	C: 54.2% T: 45.8%	C: 100% T: 0.0%
<i>IBD5_OCTN2</i> <i>SLC22A5</i>	Rs2631367	C/G (ancestral allele C)	Promoter -207	Allele “C”:35.7%	97.9%	0.07	C: 51.7% G: 48.3%	C: 60.4% G: 39.6%
<i>IBD5_OCTN2</i> <i>IGR2230</i>	Rs17622208	A/G (ancestral allele G)	Intron2	Allele “A”:18.7%	97.6%	0.15	A: 50.8% G: 49.2%	A: 10% G: 90%
<i>IBD5_IGR2198</i>	Rs11739135	C/G (ancestral allele G)	3'-UTR	Allele “G”:11.3%	96.6%	0.46	C: 42.5% G: 57.5%	G: 98.3% C: 1.7%
<i>IBD5_IGR2096</i>	Rs12521868	G/T	intergenic	Allele “T”:11.7%	97.1%	0.16	G: 55%	G: 99.2%

		(ancestral allele G)					T: 45%	T: 0.8%
<i>IL23R</i>	Rs7517847	G/T	Intron6	Allele "G":21.4%	98.6%	0.20	G: 50%	G: 11.7%
		(ancestral allele T)					T: 50%	T: 88.3%
<i>IL23R</i>	Rs2201841	C/T	Intron7	Allele "G": 13.8%	98.3%	0.55	C: 27.5%	C: 10.8%
							T: 72.5%	T: 89.2%
<i>IL23R</i>	Rs11209026	A/G	Exon9	Allele "A": 2.56%	98.6%	0.62	A: 6.8%	A: 1.7%
	Arg381Gln	(ancestral allele G)					G: 93.2%	G: 98.3%
<i>IL23R</i>	Rs1495965	A/G	intergenic	Allele "G": 44.5%	98.3%	0.30	A: 58.8%	A: 53.3%
		(ancestral allele G)					G: 41.2%	G: 46.7%
<i>IL23R</i>	Rs10889677	A/C	3'-UTR	Allele "A": 14.7%	98.2%	0.81	A: 27.5%	A: 10%
		(ancestral allele C)					C: 72.5%	C: 90%
<i>IRGM</i>	Rs4958847	A/G		Allele "A": 48.7%	98.6%	0.40	A: 9.2%	A: 55%
		(ancestral allele G)					G: 90.8%	G: 45%
<i>IRGM</i>	Rs13361189	C/T		Allele "C": 45%	98.6%	0.37	C: 2.5%	C: 53.3%
		(ancestral allele C)					T: 97.5%	T: 46.7%
<i>IRGM</i>	Rs10065172	C/T		Allele "T": 45.1%	98.7%	0.43	C: 97.5%	C: 46.5%
		(ancestral allele C)					T: 2.5%	T: 53.5%

(SUPPLEMENTARY TABLE 3) Heterogeneity test between primary and secondary replicate dataset

Marker	primary dataset						secondary dataset						Q_test	
	OR	95%CI	P	MAF	D.ca/ct	d.ca/ct	OR	95%CI	P	MAF	D.ca/ct	d.ca/ct	P	
NOD2_Cins	-	-	0.02	0.01	7/0	447/398	1.23	0.08-19.7	1.00	0.00	1/1	247/303	0.07	
NOD2.G908R_GC	1.75	0.16-19.3	1.00	0.00	2/1	452/395	2.45	0.22-27.1	0.59	0.01	2/1	246/301	0.85	
NOD2.R702W_CT	2.00	0.51-7.79	0.36	0.01	2/3	435/373	4.67	0.52-42.1	0.19	0.01	4/1	244/285	0.51	
NOD2.P268S_CT	1.54	0.87-2.72	0.16	0.06	34/20	418/378	2.07	0.96-4.47	0.08	0.05	18/11	230/291	0.54	
NOD2.R708H_GA	1.06	0.28-3.99	1.00	0.01	5/4	437/372	1.63	0.51-5.21	0.56	0.02	7/5	241/281	0.63	
NOD2.R790Q_GA	0.98	0.46-2.09	1.00	0.03	15/13	427/363	1.07	0.50-2.33	1.00	0.05	13/14	235/272	0.87	
NOD2.A725G_CG	1.20	0.61-2.36	0.61	0.04	21/15	421/361	0.56	0.22-1.42	0.27	0.04	7/14	241/272	0.19	
ATG16L_AG	1.47	1.10-1.96	0.01	0.32	163/110	291/288	1.34	0.94-1.92	0.12	0.33	89/90	155/210	0.70	
IBD5.OCTN1_CT	1.23	0.76-2.00	0.46	0.09	43/31	411/365	1.82	1.02-3.23	0.04	0.10	31/22	217/280	0.31	
IBD5.OCTN2_GC	1.38	1.05-1.83	0.02	0.39	191/137	261/259	1.10	0.78-1.56	0.59	0.38	98/108	150/182	0.32	
IGR2230_GA	1.14	0.81-1.62	0.48	0.19	88/69	358/321	1.41	0.94-2.10	0.10	0.23	64/60	182/240	0.44	
IGR2198_CG	1.29	0.82-2.02	0.31	0.11	52/36	390/348	1.39	0.88-2.21	0.19	0.16	45/41	201/255	0.81	
IGR2096_GT	1.14	0.73-1.76	0.58	0.11	52/40	394/344	1.63	1.03-2.57	0.04	0.16	50/40	198/258	0.26	
IL23_rs751_GT	1.02	0.73-1.42	0.93	0.20	93/80	361/316	0.85	0.56-1.28	0.47	0.22	49/70	193/234	0.50	
IL23_rs220_AG	1.34	0.92-1.96	0.13	0.16	78/54	370/344	1.49	0.95-2.34	0.10	0.16	47/43	193/263	0.73	
IL23_rs112_GA	1.10	0.29-4.13	1.00	0.01	5/4	447/395	0.80	0.34-1.88	0.67	0.04	9/14	233/290	0.69	
IL23_rs149_TC	1.18	0.89-1.54	0.27	0.45	207/168	239/228	0.94	0.67-1.32	0.73	0.47	112/145	132/161	0.32	
IL23_rs108_CA	1.36	0.94-1.99	0.11	0.16	79/64	369/344	1.05	0.67-1.66	0.91	0.17	41/49	201/253	0.39	
IRGM_rs495_GA	0.88	0.67-1.16	0.37	0.47	204/192	248/206	0.93	0.66-1.30	0.67	0.50	119/153	125/149	0.82	
IRGM_rs133_TC	0.94	0.72-1.23	0.68	0.44	197/178	257/218	1.05	0.75-1.47	0.80	0.46	112/137	130/167	0.61	
IRGM_rs100_CT	0.91	0.69-1.20	0.53	0.44	194/179	258/217	1.02	0.73-1.43	0.93	0.45	112/137	134/167	0.64	

MAF, minor allele frequency; D.ca/ct, minor allele cases/controls; d.ca/ct, major allele cases/controls

Heterogeneity was assessed by Q statistic. Cochran WG. The combination of estimates from different experiment. Biometrics 1954;10:101-29.

(SUPPLEMENTARY TABLE 4) Association of SNPs among 227 CD and 200 controls in primary dataset

Candidate Gene	SNP no.	0 copy of variant allele		1 copy of variant allele		2 copies of variant allele		Carrier OR (95%CI) P value	MAF case/control	Minor Allele test OR (95%CI) P value
		Case /control	OR (ref)	Case /control	OR (95%CI) p value	Case /control	OR (95%CI) P value			
<i>NOD2</i> <i>C_insertion</i>	Rs2066847 1007fs (SNP13)	220/199	1.0	7/0	8.63 (1.28--) 0.02	0/0	--	8.63 (1.28--) 0.02	1.54% / 0%	--
<i>NOD2</i> (G->C, variant C)	Rs2066845 G908R (SNP12)	225/197	1.0	2/1	1.75 (0.16-19.5) 1.00	0/0	--	1.75 (0.16-19.5) 1.0	0.44% / 0.25%	1.75 (0.16-19.3) 1.0
<i>NOD2</i> (C->T, variant T)	Rs2066844 R702W (SNP8)	214/183	1.0	7/3	2.00 (0.51-7.83) 0.32	0/0	--	1.99 (0.51-7.83) 0.36	1.58% / 0.81%	1.98 (0.51-7.71) 0.36
<i>NOD2</i> (C->T, variant T)	Rs2066842 P268S (SNP5)	196/179	1.0	26/20	1.19 (0.64-2.20) 0.58	4/0	4.79 (0.59--)	1.37 (0.75-2.50) 0.37	7.52% / 5.03%	1.54 (0.87-2.72) 0.16
<i>NOD2</i> (G->A, variant A)	rs35285618 R708H	216/182	1.0	5/4	1.05 (0.28-3.98) 1.00	0/0	--	1.05 (0.28-3.98) 1.0	1.13% / 1.07%	1.05 (0.28-3.95) 1.0
<i>NOD2</i> (G->A, variant A)	rs5743279 R790Q	206/172	1.0	15/12	1.04 (0.48-2.29) 1.00	0/0	--	1.04 (0.48-2.29) 1.0	3.39% / 3.26%	1.04 (0.48-2.26) 1.0
<i>NOD2</i> (C->G, variant G)	rs5743278 A725G	201/172	1.0	19/15	1.08 (0.53-2.20) 0.82	1/0	0.85 (0.02--)	1.14 (0.57-2.29) 0.73	4.75% / 4.01%	1.19 (0.61-2.35) 0.74
<i>ATG16L1</i> (A->G, variant G)	Rs2241880 Thr300Ala	91/108	1.0	109/72	1.80 (1.19-2.70) 0.005	27/19	1.69 (0.88-3.23) 0.11	1.77 (1.21-2.61) 0.004	35.9% / 27.6%	1.47 (1.10-1.96) 0.01
<i>IBD5_OCTN1</i> <i>SLC22A4</i> (C->T, variant T)	Rs1050152 Leu503Phe	190/167	1.0	31/31	0.88 (0.51-1.51) 0.64	6/0	7.12 (1.02--)	1.05 (0.62-1.77) 0.90	9.47% / 7.83%	1.23 (0.76-2.00) 0.46
<i>IBD5_OCTN2</i> <i>SLC22A5</i> (G->C, variant C)	Rs2631367	79/82	1.0	103/95	1.13 (0.74-1.71) 0.58	44/21	2.17 (1.19-3.98) 0.01	1.32 (0.89-1.95) 0.19	42.2% / 34.6%	1.38 (1.05-1.82) 0.02
<i>IBD5_OCTN2</i> <i>SLC22A5</i> <i>IGR2230</i> (G->A, variant A)	Rs17622208	145/128	1.0	68/65	0.92 (0.61-1.40) 0.71	10/2	4.40 (0.91-41.9) 0.07	1.03 (0.69-1.54) 0.92	19.7% / 17.7%	1.14 (0.81-1.62) 0.48
<i>IBD5_IGR2198</i> (C->G, variant G)	Rs11739135	177/156	1.0	36/36	0.88 (0.53-1.47) 0.63	8/0	9.65 (1.47--) 0.01	1.08 (0.66-1.76) 0.80	11.7% / 9.37%	1.29 (0.82-2.02) 0.31
<i>IBD5_IGR2096</i>	Rs12521868	178/152	1.0	38/40	0.81	7/0	8.13	0.96	11.7% /	1.14

<i>(G->T, variant T)</i>					(0.50-1.33)		(1.21--)	(0.60-1.55)	10.4%	(0.73-1.76)
					0.41		0.03	0.90		0.58
<i>IL23R</i>	<i>Rs7517847</i>	145/123	1.0	71/70	0.86	11/5	1.87	0.93	20.5% /	1.02
<i>(T->G, variant G)</i>					(0.57-1.29)		(0.63-5.52)	(0.62-1.38)	20.2%	(0.73-1.42)
					0.47		0.26	0.76		0.93
<i>IL23R</i>	<i>Rs2201841</i>	151/149	1.0	68/46	1.46	5/4	1.23	1.44	17.4% /	1.34
<i>(A->G, variant G)</i>					(0.94-2.26)		(0.33-4.68)	(0.94-2.20)	13.6%	(0.92-1.96)
					0.09		0.76	0.11		0.13
<i>IL23R</i>	<i>Rs11209026</i>	221/195	1.0	5/4	1.10	0/0	--	1.10	1.11% /	1.10
<i>(G->A, variant A)</i>					(0.29-4.17)			(0.29-4.17)	1.01%	(0.29-4.13)
	<i>Arg381Gln</i>				0.89			0.89		1.0
<i>IL23R</i>	<i>Rs1495965</i>	63/64	1.0	113/100	1.15	47/34	1.40	1.21	46.4% /	1.17
<i>(T->C, variant C)</i>					(0.74-1.78)		(0.80-2.46)	(0.80-1.84)	42.4%	(0.89-1.54)
					0.54		0.24	0.36		0.26
<i>IL23R</i>	<i>Rs10889677</i>	150/149	1.0	69/46	1.49	5/4	1.24	1.47	17.6% /	1.36
<i>(C->A, variant A)</i>					(0.96-2.31)		(0.33-4.71)	(0.96-2.25)	13.5%	(0.94-1.99)
					0.07		0.75	0.09		0.11
<i>IRGM</i>	<i>Rs4958847</i>	53/47	1.0	98/98	0.89	75/54	1.23	1.00	45.1% /	0.88
<i>(A->G, variant G)</i>					(0.55-1.44)		(0.73-2.08)	(0.64-1.58)	48.2%	(0.67-1.15)
					0.62		0.44	0.97		0.37
<i>IRGM</i>	<i>Rs13361189</i>	45/39	1.0	107/100	0.93	75/59	1.10	0.99	43.4% /	0.93
<i>(C->T, variant T)</i>					(0.56-1.54)		(0.64-1.91)	(0.62-1.60)	44.9%	(0.71-1.23)
					0.77		0.73	0.97		0.67
<i>IRGM</i>	<i>Rs10065172</i>	76/58	1.0	106/101	0.80	44/39	0.86	0.82	42.9% /	0.91
<i>(C->T, variant T)</i>					(0.52-1.24)		(0.50-1.49)	(0.54-1.24)	45.2%	(0.69-1.19)
					0.32		0.59	0.34		0.53

(SUPPLEMENTARY TABLE 5) Diplotype association test for *IBD5*

<u>diplotype:</u>	<u>freq.case</u>	<u>freq.ctrl</u>	<u>OR</u>	<u>95%CI</u>	<u>P value</u>
CGGCG/CGGCG	0.33	0.35	1.00 (ref)	-	-
CGGCG/CCGCG	0.23	0.26	0.91	0.60-1.37	0.7
CGGCG/TCAGT	0.09	0.11	0.93	0.52-1.64	0.88
CGGCG/CCACG	0.10	0.10	0.98	0.54-1.76	1
CCGCG/CCGCG	0.05	0.03	1.47	0.61-3.65	0.47
CCGCG/CCACG	0.04	0.02	2.42	0.76-9.03	0.16
CGGCG/CGAGT	0.01	0.05	0.25	0.03-1.31	0.12
CGAGT/CCGCG	0.00	0.02	0.42	0-5.46	0.51
CCGCG/TCAGT	0.04	0.03	1.41	0.56-3.70	0.56
CGGCG/TCAGT	0.01	0.00	3.02	0.24-160	0.63
TCAGT/TCAGT	0.02	0.00	8.14	1.16 - ∞	0.03
CCACG/TCAGT	0.02	0.01	3.02	0.53-31	0.3
CCGCG/CCAGT	0.01	0.00	5.27	0.65 - ∞	0.13
CCACG/CCACG	0.00	0.01	0.34	0.006-4.28	0.64
CGAGT/CGAGT	0.00	0.01	0.51	0.008-9.8	1

Diplotype association used PHASE Bayesian approach and partition-ligation algorithm to reconstruct haplotypes and estimate diplotype probabilities for CD and HC, separately. (Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 2001;68:978-89.) In the regression model, (CD served as the dependent variables, and the diplotype probabilities served as continuous variables.

(SUPPLEMENTARY TABLE 6)

Power calculation: Sample size 354 cases and 1:1 control; CD Population risk: 50/100,000; 2-sided p value 0.05;

	Allele freq in present study data and OR estimates from prior and present studies	Power Estimate
<i>NOD2</i> any mutant	Allele freq 1.03% in study AA HCs	
	OR 3.2 (whites) ³⁸ , log. additive mode	83%
	OR 3.3 (present data), log. additive mode	86%
<i>SLC22A4</i> (variant C)	Allele freq 7.6% in study AA HCs	
	OR 1.7 (white) ³⁰ dominant mode	78%
	OR 8.4 (present data), recessive mode	95%
<i>SLC22A5</i> (variant C)	Allele freq 35.7% in study AA HCs	
	OR 2.0 (white) ³⁰ , dominant mode	99%
	OR 1.9 (present data), recessive mode	87%
ATG16L1	Allele freq 29.3% in study AA HCs	
	OR 2.0 (white) ³⁰ , dominant mode	99%
	OR 1.4 (present data), dominant mode	62%
<i>IL23R</i> rs2201841	Allele freq 13.8% in study AA HCs	
	OR 2.2 (white) ³⁰ , dominant mode	99%
	OR 1.3 (present data), dominant mode	35%
<i>IRGM</i> rs13361189	Allele freq 45% in study AA HCs	
	OR 1.4 - 1.6 (white) ¹⁹ , dominant mode*	51 - 78%

*Taken from allelic OR. Data for mode of inheritance not available. Dominant mode assumed over additive mode as more conservative. OR from Ref 19 was 1.6, a slightly larger cohort than the Wellcome Trust discovery cohort (allelic OR of 1.4). *IRGM* power estimates are not given from present study data as OR was 0.98 (Table 2).